Sara E. Hallström, SwedenMedicinkliniken Östra Diabetes
Presenter Of 1 Presentation
CHARACTERISTICS OF CGM-METRICS IN PERSONS WITH TYPE 1 AND TYPE 2 DIABETES ON MDI-TREATMENT.
Background and Aims
The effectiveness of CGM in patients with T2D needs to be clarified regarding the effect related to treatment regimen and glucose variability. The impact of and the relation between the different CGM-metrics to HbA1c and glucose control in patients with T1D and T2D needs to be further analysed.
The two cohorts of patients with diabetes and MDI-treatment was from the same background population of sweden and 162 patients with T1D was included from the GOLD-study and 124 patients with T2D from the MDI Liraglutide trial. Both RCTs used the same CGM-system and central laboratory. The CGM-data was collected from the run-in period of both studies when the CGM was masked and no modification of treatment was done.
The patients of the two cohorts of T1D and T2D had similar mean glucose levels, 10,9 mmol/l in the patients with T1D and 10.8 mmol/l in the patients with T2D. The time in hypoglycemia was increased, 7.19 percent of the time in the patients with T1D compared to 1.27 percent of the time in the patients with T2D. The SD of the glucose levels (4.38: SD 0.73 vs 2.99:SD 0.75) and the MAGE (10.1: SD 1.7 vs 7.04: SD 1.86) was more elevated in patients with T1D compared to the patients with T2D.
Persons with T2D and MDI-treatment have much less time in hypoglycemia and less glucose variability compared to patients with T1D with similar treatment. This should be taken into account when considering modification of glucose-lowering treatments in both populations.